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Background: The α/β ratio for prostate cancer is postulated being in the range of 0.8 to 2.2 Gy, giving rise to the
hypothesis that there may be a therapeutic advantage to hypofractionation. To do so, we carried out a randomized trial
comparing hypofractionated and conventionally fractionated image-guided intensity modulated radiotherapy (IG-IMRT) in
high-risk prostate cancer. Here, we report on acute toxicity and quality of life (QOL) for the first 124 randomized patients.
Methods: The trial compares 76 Gy in 38 fractions (5 fractions/week) (Arm 1) to 63 Gy in 20 fractions (4 fractions/week)
(Arm 2) (IG-IMRT). Prophylactic pelvic lymph node irradiation with 46 Gy in 23 fractions sequentially (Arm 1) and 44 Gy
in 20 fractions simultaneously (Arm 2) was applied. All patients had long term androgen deprivation therapy (ADT)
started before RT. Both physician-rated acute toxicity and patient-reported QOL using EPIC questionnaire are described.
Results: There were no differences in overall maximum acute gastrointestinal (GI) or genitourinary (GU) toxicity.
Compared to conventional fractionation (Arm 1), GI and GU toxicity both developed significantly earlier but also
disappeared earlier in the Arm 2, reaching significant differences from Arm 1 at week 8 and 9. In multivariate analyses,
only parameter shown to be related to increased acute Grade ≥1 GU toxicity was the study Arm 2 (p = 0.049). There
were no statistically significant differences of mean EPIC scores in any domain and sub-scales. The clinically relevant
decrease (CRD) in EPIC urinary domain was significantly higher in Arm 2 at month 1 with a faster recovery at month 3 as
compared to Arm 1.
Conclusions: Hypofractionation at 3.15 Gy per fraction to 63 Gy within 5 weeks was well tolerated. The GI and GU
physician-rated acute toxicity both developed earlier but recovered faster using hypofractionation. There was a
correlation between acute toxicity and bowel and urinary QOL outcomes. Longer follow-up is needed to determine the
significance of these associations with late toxicity.Background
External-beam radiotherapy (EBRT) has a long history of
clinical use in the treatment of prostate cancer. There is a
clear demonstration from conventionally fractionated radio-
therapy dose escalation clinical trials of improved biochem-
ical relapse-free survival rates with higher irradiation doses
[1,2]. Conventionally fractionated dose escalation, however,* Correspondence: dnorkus@takas.lt
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stated.results in treatment protraction, which could negatively im-
pact patient’s lifestyle and possibly lowers biological benefit.
Hypofractionation in the treatment of prostate cancer offers
a shorter treatment course and increased convenience for
patients [3-10].
There is increasing evidence that the α/β ratio for pros-
tate cancer may be low and is in the range of 0.8 to 2.2 Gy
[11]. If the prostate cancer α/β value is consistently lower
than the appropriate values considered for late normal-
tissue morbidity, significant increases in tumor control can
be expected by changing from conventional fractionationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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acute and late toxicity. The fear of severe acute and late
genitourinary (GU) and gastrointestinal (GI) toxicity has
been an argument against hypofractionated dose escalation
to the prostate and pelvic lymph nodes. However, planning
studies have proved that IMRT enables the combination of
better target coverage and sparing of the OARs [12]. The
results to date support the conclusion that hypofractionated
radiation therapy is relatively safe for the treatment of local-
ized prostate cancer. No significant increase has been seen
in the acute toxicity or the late adverse events as compared
to standart dose regiments [3-6].
Most reports from prostate cancer hypofractionated
EBRT studies have focused on physician-rated toxicities.
Only some have used validated patient-reported quality
of life (QOL) questionnaires [5-10]. We found QOL
outcomes important because they are not well corre-
lated with physician-related toxicities [13].
In this interim report we describe both, physician-
related acute toxicities and patient-reported QOL mea-
surements by validated Expanded Prostate Cancer Index
Composite (EPIC), from the prospective randomized
trial comparing hypofractionated and conventionally
fractionated image guided IMRT (IG-IMRT) combined
with androgen deprivation therapy for the first 124 high




Between January 2010 and May 2012, 124 consecutive pa-
tients were enrolled in this study. The inclusion criteria were
as follows: histologically proven prostate adenocarcinoma;
prostate-specific antigen (PSA) level ≤100 ng/ml; ECOG
performance status <2; no evidence of distant metastases;
no other malignancy except basal cell skin cancer; no con-
traindications for androgen deprivation therapy (ADT); no
previous prostate surgery including transurethral resection;
and most importantly, high risk features according to
NCCN criteria: stage T3a-T3b, biopsy Gleason score (GS)
of 8–10; pretreatment PSA level (iPSA) >20 ng/mL, or the
presence of at least two of the following clinical characteris-
tics: iPSA of 11–20 ng/ mL, T ≥2c, GS =7. Exclusion cri-
teria included lymph node involvement and previous RT to
the pelvis.
Study design
The present Phase III, randomized trial design was formu-
lated to test the hypothesis that compared with a conven-
tional fractionation of 76 Gy in 38 fractions (5 fractions/
week) at 2.0 Gy/fraction (Arm 1), the delivery of 63 Gy in
20 fractions (4 fractions/week) at 3.15 Gy/fraction (Arm 2,
hypofractionation) to the prostate and seminal vesicles
would be more effective while maintaining same rates ofacute and late complications as well as patient-reported
QOL changes. The pelvic lymph nodes were irradiated se-
quentially delivering 46 Gy at 2 Gy/fraction (Arm 1) or
simultaneously – 44 Gy at 2.2 Gy/fraction (Arm 2). The
hypofractionation regimen to the prostate and seminal
vesicles was hypothesized to be equivalent to 84 Gy EQD2
assuming an α/β ratio of 1.5 Gy. The hypothesized differ-
ence of 8 Gy between Arm 1 and Arm 2 potentially results
in a 15% gain in freedom from biochemical failure (FFBF)
[14]. To detect this gain with 80% power and statistical
significance (p < 0.05, two-sided), 120 patients were re-
quired in each group (240 total). With the regard to the
pelvic lymph nodes both regimens hypothesized to be
similar: 46 Gy (Arm 1) and 46.5 Gy (Arm 2) assuming an
α/β ratio of 1.5 Gy. The protraction of hypofractionation
regimen from 4 to 5 weeks (4 fractions/week) allowed to
keep the acute mucosal time-corrected BED below
63 Gy10 limit to achieve tolerable acute reactions [15].
After institutional ethics board and Lithuanian Bioethics
Committee approval the study started in 2010. The pa-
tients were enrolled and assigned to the study group with
a balanced randomization method using a computer pro-
gram. No blinding was possible. The study was scheduled
to be completed within 5 years.
Treatment
All patients were instructed to use Fleet enema in the
morning of CT simulation day to empty the rectum, to
urinate and drink 400 ml of water 30 minutes before CT
simulation. CT simulation was performed in the supine
position with knee and ankle fixing device. Patients were
scanned with 2.5 mm thick slices from fourth lumbar ver-
tebra to 3 cm below ischial bones. The entire prostate was
outlined as CTVp, entire seminal vesicles as CTVsv. Pelvic
lymph nodes were outlined as CTVln following RTOG
consensus guidelines [16]. To obtain the planning target
volume of the prostate (PTVp), the CTVp was expanded in
X, Y, and Z direction with a 10 mm margin, except poster-
iorly where a 7 mm margin was added. CTVsv was ex-
panded to PTVsv with 10 mm in all directions, and CTVln
to PTVln with a 5 mm margin. PTVp and PTVsv were
merged into PTV1, PTVln - into PTV2. Rectum was
outlined as a solid organ from rectosigmoid flexure down
to the bottom of ischial bones. Bladder was also outlined
as a solid organ. Large and small bowel were outlined as
one structure, up to 10 mm above PTV2, encompassing
the entire abdominal cavity.
All study patients underwent planning with Eclipse v.
10.0 (Varian Medical Systems, Palo Alto, CA) and sliding
windows delivery. Treatment plans were generated using 5
to 7 co-planar photon beams of 6 MV. PTV1 and PTV2
were set to receive between 95% and 108%, clinical target
volumes – between 99% to 108% of the prescription dose.
Two sequential plans were made for Arm 1. Phase 1
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2 contained an additional 15 fractions of 2.0 Gy to PTV1.
Arm 2 patients were planned to treat with a simultaneously
integrated boost (SIB), giving 20 fractions of 3.15 Gy to
PTV1 and 20 fractions of 2.2 Gy to PTV2, using 4 fractions
per week. With regard to OARs, both phases were com-
bined in the Arm 1 plans and dose/volume restrictions were
as following: rectum – maximum dose (Dmax) <80 Gy, vol-
ume receiving 55 Gy (V55) <50%, V70 <30%; bladder –
Dmax <80 Gy, V55 <50%, bowel – Dmax <55 Gy, femoral
heads – Dmax <50 Gy. Arm 2 plans had equivalent restric-
tions: rectum – Dmax <64.2 Gy, V50 <50%, V58 <30%;Table 1 Patients characteristics and dosimetric
parameters
Arm 1 Arm 2
N 57 67
Age (years)
Median (range) 64 (51–75) 66 (50–76)
Gleason score
≤7 49 (86%) 64 (95%)
>7 8 (14%) 3 (5%)
cT-stage
<T2c 11 (19%) 12 (18%)
≥T2c 46 (81%) 55 (82%)
iPSA
≤20 ng/ml 40 (70%) 57 (85%)
>20 ng/ml 17 (30%) 10 (15%)
PTV volume
PTVP ± SE (cc) 116 ± 35 116 ± 31
PTVSV ± SE (cc) 92 ± 25 92 ± 17
PTVLN ± SE (cc) 608 ± 89 613 ± 102
Bladder
Total volume ± SE (cc) 139 ± 94 125 ± 60
V52.6% ± SE (cc) 101 ± 54 113 ± 51
V65.8% ± SE (cc) 71 ± 35 79 ± 30
V78.9% ± SE (cc) 47 ± 20 51 ± 19
V92% ± SE (cc) 31 ± 12 34 ± 13
V100% ± SE (cc)* 16 ± 8 20 ± 12
Rectum
Total volume ± SE (cc) 70 ± 16 69 ± 17
V52.6% ± SE (cc)* 43 ± 12 54 ± 15
V65.8% ± SE (cc)* 30 ± 10 37 ± 12
V78.9% ± SE (cc)* 21 ± 7 24 ± 9
V92% ± SE (cc) 14 ± 5 15 ± 6
V100% ± SE (cc)* 4 ± 4 7 ± 5
Abbreviations: Arm 1 = conventional fractionation; Arm 2 = hypofractionation.
*p <0.05 between groups, two-sample t test.bladder – Dmax <64.2 Gy, V50 <50%, bowel – Dmax
<50 Gy, femoral heads – Dmax <48 Gy.
Daily image guidance with kV cone beam CT (CBCT)
with linac mounted on board imager (OBI - Varian Med-
ical Systems, Palo Alto, CA) was implemented. After the
accomplishment of the matching procedures, the final
correction parameters were automatically applied to the
treatment couch and the patient was subsequently treated.
All patients received ADT (LHRH agonist only), which
typically started 3–4 months before RT and continued
for a total duration of ≥6 months. All patients received
ADT concurrent with pelvic RT.
Follow-up
Acute GU and GI toxicity was evaluated using the Radi-
ation Therapy Oncology Group/European Organization
for Research and Treatment of Cancer (RTOG-EORTC)
system, extended by additional symptoms [17]. Patients
were evaluated weekly during 12 weeks starting from the
beginning of irradiation.
Patient-reported QOL outcomes were collected at the
baseline and then monthly during acute period of treat-
ment. The EPIC questionnaire with validated 50 items for
measurement of prostate cancer specific health related
QOL was used [18].
To date only data on acute toxicity and QOL during the
acute period of treatment of the first 124 patients are
presented in this interim analysis.
Statistical analysis
Two-sample t tests were used to assess differences between
the dosimetric parameters and GU and GI toxicity between
the treatment arms. Confirmatory analyses were performed
using nonparametric Wilcoxon tests. Stepwise ordinal lo-
gistic regression modeling was used to determine inde-
pendent predictors of GU and GI toxicity. The variables for
the acute toxicity were GU and GI grade ≥ 1, ≥ 2 and ≥ 3.
Covariates included: rectal volume, bladder volume, rectal
and bladder dose/volume cut-points (V40 Gy/V33 Gy, V50
Gy/V42 Gy, V60 Gy/V50 Gy, V70 Gy/V58 Gy, and V76
Gy/V63 Gy) and treatment group (Arm 1 vs. Arm 2).
The baseline EPIC scores (T0) were collected before the
start of the treatment. The T1 scores reflects the change in
QOL during first 4 weeks of treatment, T2 – during week 5
to 8, T3 – week 9 to 12. The baseline EPIC score was the
mean score of all patients from both treatment arms. A
simple subtraction of the baseline score (T0) from the sub-
sequent time points scores (T1-3) was calculated for each
patient. The average changes from the baseline score in
each EPIC score were then compared between treatment
arms at each time point using two-sample t-test, with the
level of significance of p < 0.05. The one-way analysis of
variance (ANOVA) for repeated measurements of EPIC
mean scores between treatment arms was also performed.
Table 2 Maximum and week 12 acute GU and GI toxicity
Group Max GU toxicity Max GI toxicity
Grade 0 1 2 3 0 1 2 3
Arm 1 10 (18%) 31 (54%) 12 (21%) 4 (7%) 16 (28%) 18 (32%) 23 (40%) 0 (0%)
Arm 2 8 (12%) 43 (64%) 11 (16%) 5 (7%) 17 (25%) 24 (36%) 26 (39%) 0 (0%)
Fisher’s test p NS NS NS NS NS NS NS -
GU toxicity at week 12 GI toxicity at week 12
Arm 1 28 (55%) 21 (41%) 2 (4%) 0 (0%) 36 (71%) 8 (16%) 7 (13%) 0 (0%)
Arm 2 46 (85%) 7 (13%) 1 (2%) 0 (0%) 48 (89%) 4 (7%) 2 (4%) 0 (0%)
Fisher’s test p 0.001 0.002 NS - 0.027 NS NS -
Abbreviations: Arm 1 = conventional fractionation; Arm 2 = hypofractionation; NS = difference not significant (p < 0.05).
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fined as a difference from baseline (T0) to follow-up (T1-3)
that exceeded half a standard deviation of the baseline value
at month 1, 2 and 3 was compared among the study arms
using two-sample t test. The analyses were conducted using
StatView (SAS Institute Inc. USA).Results
All 124 patients completed the planned radiotherapy
(Arm 1–57, Arm 2–67) and were followed for at least for
3 months from the beginning of irradiation (median – 7,
range, 3–12 months). There were no protocol violations
in terms of inclusion criteria and dose/volume restrictions
of treatment plans. Patient compliance was good reaching
93% (53 patients) in Arm 1 and 88% (59 patients) in Arm
2 at 3 months follow-up. The pretreatment characteristics
and dosimetric parameters are outlined in Table 1. The
recorded characteristics of age, Gleason score, cT stage,
and iPSA level appeared to be balanced between both
study arms. OAR dosimetric characteristics are V52.6%,
V65.8%, V78.9%, V92% and V100% which represents bladder
and rectum volumes receiving 40 Gy and 33 Gy, 50 Gy
and 42 Gy, 60 and 50 Gy, 70 Gy and 58 Gy, 76 and 63 Gy
for Arm 1 and Arm 2, respectively. We found statistically
higher volume percentages of the rectum treated to more
than both the high (V100%, V78.9%) and low (V52.6%, V65.8%)Figure 1 Weekly changes in the mean GU and GI toxicity.dose cut-points in Arm 2, as compared with Arm 1. A
similar pattern was observed for the bladder V100%.Acute toxicity
The treatment was well tolerated in both arms with 28%
and 25% of patients with no GI toxicity and 18% and 12%
experiencing no GU toxicity during and after conventional
fractionation (Arm 1) and hypofractionation (Arm 2), re-
spectively. There were no Grade 4 acute GU or GI events
and only 7% Grade 3 GU toxicities in both Arms 1 and 2.
The maximum acute GU and GI toxicity that was observed
weekly during the first 3 months from the start of the treat-
ment is displayed in Table 2. The majority of patients in
both Arms 1 and 2 experienced Grade 1–2 GU and GI side
effects. The difference between study arms was not statisti-
cally significant (p > 0.05). At the 3 months from the start
of radiotherapy, there were 55% and 85% in Arms 1 and 2
experiencing no GU toxicity; the difference was statistically
significant (p < 0.05).
The weekly maximum GU and GI toxicity (mean values)
is displayed in Figure 1, demonstrating that there was an
increase in the maximum GI toxicity in Arm 2 at weeks 3,
4 and 5 of the treatment, as compared to arm 1. However,
those differences between study arms were not significant
(p > 0.05). The same figure demonstrates a significant de-
crease in the mean maximum GI toxicity in Arm 2
Table 3 EPIC scores (± SE) at each time point
Time points Baseline 1 month 2 months 3 months p-value
(ANOVA)Arm 1/2 1 2 1 2 1 2
N =124 =55 =67 =54 =56 =51 =54
Urinary domain 91.9 84.3 (2.0) 81.0 (1.9) 81.9 (2.0) 81.7 (2.2) 87.5 (1.8) 91.1 (1.8) 0.5470
Function 97.5 91.3 (1.7) 92.1 (1.5) 91.6 (18) 90.6 (1.8) 95.3 (1.6) 95.4 (1.5) 0.8058
Bother 87.9 79.4 (2.5) 73.0 (2.6) 75.0 (2.6) 75.4 (3.0) 82.0 (2.4) 87.9 (2.4) 0.4913
Incontinence 97.1 94.8 (1.4) 93.8 (1.5) 93.7 (1.6) 91.7 (2.1) 96.6 (1.6) 95.6 (1.7) 0.8293
Irritative/obstructive 89.5 79.2 (2.6) 74.7 (2.5) 76.5 (2.6) 77.0 (2.8) 83.3 (2.3) 88.1 (2.3) 0.4556
Bowel domain 95.8 82.7 (2.7) 80.1 (2.5) 84.1 (2.8) 78.1 (3.2) 89.7 (2.6) 92.6 (1.7) 0.9208
Function 95.6 82.3 (2.6) 77.1 (2.6) 83.7 (3.0) 76.6 (3.2) 89.3 (2.8) 91.0 (2.1) 0.7569
Bother 95.8 82.7 (2.7) 80.1 (2.5) 84.1 (2.8) 78.1 (3.2) 89.7 (2.6) 92.6 (1.7) 0.9208
N =121 =53 =66 =53 =55 =50 =53
Sexual domain 28.6 22.1 (2.4) 22.0 (2.9) 26.1 (3.0) 26.1 (3.1) 23.2 (3.2) 24.2 (3.4) 0.3919
Function 16.0 8.6 (2.8) 8.1 (3.2) 11.1 (3.2) 11.3 (3.4) 9.5 (3.3) 10.4 (3.9) 0.6457
Bother 56.9 52.4 (5.0) 53.2 (4.9) 59.9 (5.9) 59.4 (6.3) 54.0 (5.7) 55.3 (6.0) 0.3805
Hormonal domain 83.9 83.6 (1.8) 84.7 (1.3) 86.2 (1.8) 83.5 (2.0) 85.1 (2.2) 86.5 (1.9) 0.9304
Function 75.9 76.0 (2.7) 77.7 (2.4) 79.0 (2.6) 75.4 (3.6) 77.3 (2.9) 80.6 (2.6) 0.9012
Bother 90.5 90.0 (1.3) 90.5 (1.1) 92.3 (1.5) 90.2 (1.6) 91.7 (2.0) 91.5 (2.0) 0.7273
Abbreviations: Arm 1 = conventional fractionation; Arm 2 = hypofractionation; N = number of patients.
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0.05). In concordance, as compared to Arm 1, there was
a significant increase in mean maximum GU toxicity
seen in the Arm 2 at week 1 and 2 (p = 0.06, p = 0.016),
but, again, the figure demonstrated a significant de-
crease of the same toxicity in Arm 2 at week 8, 9, 10, 11
and 12 (p < 0.05).
In the multivariate analysis via logistic regression the
only covariate shown to be related to increased acute
Grade ≥1 GU reactions was the study arm (Arm 1 vs.Figure 2 Mean change from baseline ± SE of urinary domain and subArm 2, p = 0.049). Neither dosimetric or volume param-
eters were significant.
Quality of life
The mean EPIC scores for each domain at baseline and
months 1, 2 and 3 were summarized in Table 3.
Monthly changes in the mean and SEs for EPIC scores
for urinary and bowel domains are displayed in Figure 2
and Figure 3. There are no statistically significant dif-
ferences of mean EPIC scores in any domain and sub-scales.
Figure 3 Mean change from baseline ± SE of bowel domain and subscales.
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reported urinary and bowel domains is deeper at month 1
and 2 in Arm 2. However, the faster recovery of quality of
life parameters at month 3 is observed in the same group
of patients.
The proportion of patients with CRD of EPIC scores in
the urinary and bowel domains are summarized in Table 4.
The CRD in urinary domain was significantly higher in
Arm 2 at month 1. The proportion of the same group of
patients was significantly lower at month 3 from the start of
treatment. The proportions of CRD in quality of life related
to bowel toxicity were not significant between study arms.
Discussion
The published data for hypofractionation schedules have
had a large variability in the treatment regimens, with a
range of 5–28 fractions delivered within 3– 5.5 weeks
[19,20]. Data on toxicity are controversial and sparse. A
few studies have reported the results using high-dose
“prostate-only” hypofractionated regimens for the treat-
ment of localized prostate cancer. The acute Grade 2 or
greater GI and GU toxicity rates reported in these series
ranged from 2% to 35% and 8% to 47%, respectively [3,21].
The acute effects observed for the patients treated herein
are in concordance with the studies applying “whole pelvis”
IMRT, although there were some differences. We describe
about a 40% rate of Grade 2 or higher maximum gastro-
intestinal reactions in both treatment arms, whereas the
rates of other institutional reports are ranging from 0% to
80%, depending on clinical assessment and criteria usedTable 4 Clinically relevant decrease (CRD) in EPIC urinary
and bowel domains













Arm 1 40% 59% 37% 53% 48% 29%
Arm 2 57% 54% 20% 66% 61% 28%
t-test p = 0.045 NS p = 0.002 NS NS NS
Abbreviations: Arm 1 = conventional fractionation; Arm 2 = hypofractionation;
NS = difference not significant (p < 0.05).[22,23]. The drop in Grade 2 or higher acute GI toxicity to
13% and 4% in our study Arm 1 and Arm 2, respectively,
at 3 months from the start of radiotherapy is noteworthy.
In terms of Grade 2 or higher GU reactions, the rates
reported from “whole pelvis” IMRT studies are 37% to
60% [22,23]. Therefore, our findings of 28% and 23% in
the Arm 1 and Arm 2 respectively are at the lower end.
More importantly, by 3 months from the start of radio-
therapy, only 1 patient (2%) in Arm 1 and 2 patients (4%)
in Arm 2 experienced still Grade 2 GU toxicity.
Compared to Arm 1, GI and GU toxicity both developed
significantly earlier but also disappeared earlier in Arm 2.
Furthermore, in patients experiencing Grade 2 or greater
toxicity, no difference was found in the maximum GI and
GU toxicity during 3 months from the start of treatment.
Based on our data, we were not able to define clear risk
factors for developing acute GU or GI toxicity after Arm 1
and Arm 2 regimens. In our study the pelvic lymph node
irradiation was comparable in both treatment arms (Arm
1 – 23 x 2.0 Gy, Arm 2 – 20 x 2.2 Gy). We believe it plays
key role in the development of acute GI toxicity.
It is worth noting that the pre-sacral lymph nodes
were generally not irradiated in the majority of “whole
pelvis” IMRT series [24]. The inclusion of pre-sacral
lymph nodes recently recommended by RTOG guide-
lines [16] possibly had an impact on acute GI toxicity
rate in our study.
We assessed the impact of our Arm 1 and Arm 2 regi-
mens on urinary, rectal, and sexual QOL. Although the
results from many prospective studies of hypofrac-
tionated RT have been reported, almost all have used
only physician-rated toxicity. Hypofractionated RT stud-
ies with QOL endpoints are sparse with patients com-
pleting EPIC questionnaires after at least 6 months
follow-up. The results using this questionnaire during
acute period of treatment were reported in two series
[25,26]. First prospective study reported QOL outcomes
with EPIC questionnaires completed at the baseline and
at months 2, 6, 12 and 24. Our Arm 1 regimen seems to
be similar to conventional radiation outcomes from this
series with an early bowel-related decrease in QOL
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at months 1 and 3 makes the comparison with this series
difficult. Second phase 1 “prostate-only” dose escalation
trial used EPIC questionnaires at the baseline, month 2, 3
and beyond. The mean EPIC scores for bowel and urinary
seems to be similar with ours and with the decrease of
QOL parameters at month 2 with partial to full recovery at
month 3 [26]. Overall we found good correlation be-
tween physician-rated GU and GI toxicity and patient-
reported QOL outcomes. The deeper worsening of
urinary and bowel mean EPIC scores at month 1 and 2
with the faster recovery of those parameters at month 3
is observed in the Arm 2. Those differences were not
signifficant. Only the proportion of patients experien-
cing CRD in urinary domain in Arm 2 was signifficantly
higher at month 1 and signifficantly lower at month 3
when comparing with Arm 1.
Conclusions
In conclusion, there was a small, but significant increase in
acute GU reactions at Weeks 1–2 of treatment in the
hypofractionation arm. The GI and GU toxicity both devel-
oped earlier but recovered faster using hypofractionation.
Overall, there was little difference in maximum acute mor-
bidity between the conventional and hypofractionation
randomization arms of the IG-IMRT based treatments.
Dose–volume criteria were not related to treatment-related
increases in acute GI and GU reactions. There was a correl-
ation between acute toxicity and bowel and urinary QOL
outcomes. Longer follow-up is needed to determine the sig-
nificance of these associations with late toxicity.
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